News articles about Pluristem Therapeutics (NASDAQ:PSTI) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.3394709826628 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities research analysts recently weighed in on the stock. Maxim Group set a $3.00 price target on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a report on Thursday, November 9th. Seaport Global Securities reiterated a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Finally, ValuEngine cut shares of Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $3.83.
Pluristem Therapeutics (PSTI) traded up $0.09 during trading hours on Monday, reaching $1.61. 933,500 shares of the company were exchanged, compared to its average volume of 436,956. Pluristem Therapeutics has a 1-year low of $1.04 and a 1-year high of $2.12. The company has a market capitalization of $175.14, a price-to-earnings ratio of -5.03 and a beta of 0.09.
WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://baseballnewssource.com/markets/pluristem-therapeutics-psti-receiving-somewhat-favorable-media-coverage-study-finds/1819311.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.